{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:57Z","timestamp":1787002677467,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["J3578-B21"],"award-info":[{"award-number":["J3578-B21"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 4701"],"award-info":[{"award-number":["FWF-SFB 4701"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 4704"],"award-info":[{"award-number":["FWF-SFB 4704"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 6103"],"award-info":[{"award-number":["FWF-SFB 6103"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 6106"],"award-info":[{"award-number":["FWF-SFB 6106"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 6107"],"award-info":[{"award-number":["FWF-SFB 6107"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P24295-B23"],"award-info":[{"award-number":["P24295-B23"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 4706"],"award-info":[{"award-number":["FWF-SFB 4706"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF-SFB 6101"],"award-info":[{"award-number":["FWF-SFB 6101"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41375-018-0369-5","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T04:04:04Z","timestamp":1548302644000},"page":"1583-1597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Twins with different personalities: STAT5B\u2014but not STAT5A\u2014has a key role in BCR\/ABL-induced leukemia"],"prefix":"10.1038","volume":"33","author":[{"given":"Sebastian","family":"Kollmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Grundschober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Warsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Grausenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Huuhtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Hennighausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-0620","authenticated-orcid":false,"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hoelbl-Kovacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"369_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161\u201370.","journal-title":"N Engl J Med"},{"key":"369_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673\u201383.","journal-title":"Nat Rev Cancer"},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin, RA, Bertrand, FE, McCubrey, JA. JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189\u2013218.","journal-title":"Leukemia"},{"key":"369_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R. The STATs of cancer\u2014new molecular targets come of age. Nat Rev Cancer. 2004;4:97\u2013105.","journal-title":"Nat Rev Cancer"},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1097-2765(00)00067-8","volume":"6","author":"J Schwaller","year":"2000","unstructured":"Schwaller J, Parganas E, Wang D, Cain D, Aster, JC, Williams IR, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL\/JAK2. Mol Cell. 2000;6:693\u2013704.","journal-title":"Mol Cell"},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria","year":"1996","unstructured":"Ilaria RL, Van Etten RA. P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704\u201310.","journal-title":"J Biol Chem"},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0301-472X(01)00787-1","volume":"30","author":"K Spiekermann","year":"2002","unstructured":"Spiekermann K, Pau M, Schwab R, Schmieja K,Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol. 2002;30:262\u201371.","journal-title":"Exp Hematol"},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","volume":"107","author":"A Hoelbl","year":"2006","unstructured":"Hoelbl A, Kovacic B, Kerenyi MA, Simma, O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 2006;107:4898\u2013906.","journal-title":"Blood"},{"key":"369_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA,et al. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol Med. 2010;2:98\u2013110.","journal-title":"EMBO Mol Med"},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1101\/gad.11.2.179","volume":"11","author":"X Liu","year":"1997","unstructured":"Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11:179\u201386.","journal-title":"Genes Dev"},{"key":"369_CR11","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1101\/gad.1840109","volume":"23","author":"D Yamaji","year":"2009","unstructured":"Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson, GW,\u00a0et al. Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev. 2009;23:2382\u20137.","journal-title":"Genes Dev"},{"key":"369_CR12","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.1073\/pnas.92.19.8831","volume":"92","author":"X Liu","year":"1995","unstructured":"Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA. 1995;92:8831\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"369_CR13","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1073\/pnas.94.14.7239","volume":"94","author":"GB Udy","year":"1997","unstructured":"Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA. 1997;94:7239\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"key":"369_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","volume":"7","author":"R Moriggl","year":"2005","unstructured":"Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K,\u00a0Gingras S, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7:87\u201399.","journal-title":"Cancer Cell"},{"key":"369_CR15","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1128\/MCB.18.7.3871","volume":"18","author":"M Onishi","year":"1998","unstructured":"Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871\u20139.","journal-title":"Mol Cell Biol"},{"key":"369_CR16","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.4049\/jimmunol.171.11.5853","volume":"171","author":"MA Burchill","year":"2003","unstructured":"Burchill MA, Goetz CA, Prlic M, O'Neil JJ, Harmon IR, Bensinger SJ, et al. Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol. 2003;171:5853\u201364.","journal-title":"J Immunol"},{"key":"369_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4049\/jimmunol.170.1.210","volume":"170","author":"J Kelly","year":"2003","unstructured":"Kelly J, Spolski R, Imada K, Bollenbacher J, Lee S, Leonard WJ.\u00a0A role for Stat5 in CD8\u2009+\u2009T cell homeostasis. J Immunol. 2003;170:210\u20137.","journal-title":"J Immunol"},{"key":"369_CR18","first-page":"6517","volume":"61","author":"M Nieborowska-Skorska","year":"2001","unstructured":"Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G. et\u00a0al. Role of signal transducer and activator of transcription 5 in nucleophosmin\/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001;61:6517\u201323.","journal-title":"Cancer Res"},{"key":"369_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/nm1659","volume":"13","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med. 2007;13:1341\u20138.","journal-title":"Nat Med"},{"key":"369_CR20","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","volume":"121","author":"HLM Rajala","year":"2013","unstructured":"Rajala HLM, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S. et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541\u201350.","journal-title":"Blood"},{"key":"369_CR21","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2014.89","volume":"28","author":"M Kontro","year":"2014","unstructured":"Kontro M, Kuusanm\u00e4ki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O. et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28:1738\u201342.","journal-title":"Leukemia"},{"key":"369_CR22","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.3324\/haematol.2014.104992","volume":"99","author":"OR Bandapalli","year":"2014","unstructured":"Bandapalli OR, Schuessele S, Kunz JB, Rausch T, St\u00fctz AM, Tal N. et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica. 2014;99:e188\u201392.","journal-title":"Haematologica"},{"key":"369_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"MJ Kiel","year":"2014","unstructured":"Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124:1460\u201372.","journal-title":"Blood"},{"key":"369_CR24","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2014.200","volume":"28","author":"A Nicolae","year":"2014","unstructured":"Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, et al. Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas. Leukemia. 2014;28:2244\u20138.","journal-title":"Leukemia"},{"key":"369_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36:503\u201314.","journal-title":"Immunity"},{"key":"369_CR26","doi-asserted-by":"publisher","first-page":"24407","DOI":"10.1074\/jbc.M909771199","volume":"275","author":"K Ariyoshi","year":"2000","unstructured":"Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000;275:24407\u201313.","journal-title":"J Biol Chem"},{"key":"369_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1172\/JCI94509","volume":"128","author":"HTT Pham","year":"2017","unstructured":"Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri\u00a0T, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2017;128:387\u2013401.","journal-title":"J Clin Invest"},{"key":"369_CR28","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123:3951\u201362.","journal-title":"Blood"},{"key":"369_CR29","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood-2016-06-724856","volume":"128","author":"EI Andersson","year":"2016","unstructured":"Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128:2465\u20138.","journal-title":"Blood"},{"key":"369_CR30","doi-asserted-by":"crossref","unstructured":"Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9:1567","DOI":"10.1038\/s41467-018-03987-2"},{"key":"369_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2006.05.025","volume":"10","author":"B Kovacic","year":"2006","unstructured":"Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell. 2006;10:77\u201387.","journal-title":"Cancer Cell"},{"key":"369_CR32","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, H\u00f6lbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409\u201320.","journal-title":"Blood"},{"key":"369_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/0008-5472.CAN-12-0255","volume":"73","author":"WF Tam","year":"2013","unstructured":"Tam WF, H\u00e4hnel PS, Sch\u00fcler A, Lee BH, Okabe R, Zhu N, et al. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res. 2013;73:373\u201384.","journal-title":"Cancer Res"},{"key":"369_CR34","doi-asserted-by":"crossref","unstructured":"Liu W, Liu X, Yu W-M, Bunting KD, Qu C-K. Critical role of Stat5 in the maintenance of leukemic stem cells in Ptpn11-associated juvenile myelomonocytic leukemia. Blood. 2014;124:818","DOI":"10.1182\/blood.V124.21.818.818"},{"key":"369_CR35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1172\/JCI200422315","volume":"114","author":"D Stoiber","year":"2004","unstructured":"Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R,\u00a0et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest. 2004;114:1650\u20138.","journal-title":"J Clin Invest"},{"key":"369_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.celrep.2013.07.012","volume":"4","author":"EM Putz","year":"2013","unstructured":"Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, et al. CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. Cell Rep. 2013;4:437\u201344.","journal-title":"Cell Rep"},{"key":"369_CR37","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1084\/jem.188.11.2067","volume":"188","author":"K Imada","year":"1998","unstructured":"Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188:2067\u201374.","journal-title":"J Exp Med"},{"key":"369_CR38","doi-asserted-by":"crossref","unstructured":"Villarino A, Laurence A, Robinson GW, Bonelli M, Dema B, Afzali B, et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. eLife. 2016;5.e08384","DOI":"10.7554\/eLife.08384"},{"key":"369_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0006-291X(03)01382-2","volume":"308","author":"S Uddin","year":"2003","unstructured":"Uddin S, Lekmine F, Sassano A, Rui H, Fish, EN, Platanias LC, et al. Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun. 2003;308:325\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"369_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4049\/jimmunol.174.2.609","volume":"174","author":"Y Tanabe","year":"2005","unstructured":"Tanabe Y, Nishibori T, Su L, Arduini, RM, Baker DP, David M. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol. 2005;174:609\u201313.","journal-title":"J Immunol"},{"key":"369_CR41","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.4049\/jimmunol.173.10.6241","volume":"173","author":"R Gonsky","year":"2004","unstructured":"Gonsky R, Deem RL, Bream J, Young HA, Targan SR. Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression. J Immunol. 2004;173:6241\u20137.","journal-title":"J Immunol"},{"key":"369_CR42","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cub.2005.08.036","volume":"15","author":"C Wellbrock","year":"2005","unstructured":"Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol. 2005;15:1629\u201339.","journal-title":"Curr Biol"},{"key":"369_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.immuni.2012.01.011","volume":"36","author":"DJ Gough","year":"2012","unstructured":"Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 2012;36:166\u201374.","journal-title":"Immunity"},{"key":"369_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131\u201344.","journal-title":"Nat Rev Cancer"},{"key":"369_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.430","volume":"7","author":"Z Ren","year":"2016","unstructured":"Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP,\u00a0et al. Phosphorylated STAT5 regulates p53 expression via BRCA1\/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7:e2560.","journal-title":"Cell Death Dis"},{"key":"369_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cyto.2016.01.013","volume":"82","author":"UK Mukhopadhyay","year":"2016","unstructured":"Mukhopadhyay UK, Cass J, Raptis L, Craig AW, Bourdeau V, Varma S, et al. STAT5A is regulated by DNA damage via the tumor suppressor p53. Cytokine. 2016;82:70\u201379.","journal-title":"Cytokine"},{"key":"369_CR47","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2014.60","volume":"34","author":"M Girardot","year":"2015","unstructured":"Girardot M, Pecquet C, Chachoua I, Van Hees J, Guibert S, Ferrant A, et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene. 2015;34:1323\u201332.","journal-title":"Oncogene"},{"key":"369_CR48","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1593\/neo.12878","volume":"14","author":"C Moser","year":"2012","unstructured":"Moser C, Ruemmele P, Gehmert S, Guibert S, Ferrant A, Knoops L, et al. STAT5b as molecular target in pancreatic cancer\u2014inhibition of tumor growth, angiogenesis, and metastases. Neoplasia. 2012;14:915\u201325.","journal-title":"Neoplasia"},{"key":"369_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2341","volume":"11","author":"TM Bernaciak","year":"2009","unstructured":"Bernaciak TM, Zareno J, Parsons JT, Silva CM. A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrin-mediated human breast cancer cell migration. Breast Cancer Res. 2009;11:R52.","journal-title":"Breast Cancer Res"},{"key":"369_CR50","doi-asserted-by":"crossref","unstructured":"Najjar I, Grimont A, Martin N, Martin-Lanneree S, Bonnet ML, Guilhot F, et al. Distinct functions of Stat5A and Stat5B in chronic myeloid leukemia (CML): Stat5B is implicated in survival and self-renewal and Stat5A in imatinib resistance. Blood. 2010;116:1214.","DOI":"10.1182\/blood.V116.21.1214.1214"},{"key":"369_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","volume":"27","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Hehlmann R, Quint\u00e1s-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803\u201312.","journal-title":"Leukemia"},{"key":"369_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","volume":"18","author":"LA Kujawski","year":"2007","unstructured":"Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459\u201371.","journal-title":"Cytokine Growth Factor Rev"},{"key":"369_CR53","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian J-J, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706\u201315.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0369-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:36:39Z","timestamp":1684604199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0369-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0369-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SM has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb (not related to this study). The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}